Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

NCT02024646 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

484

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriatic Arthritis

Interventions

DRUG: 210 mg brodalumab
DRUG: 140 mg brodalumab
DRUG: Placebo

Sponsor

Bausch Health Americas, Inc.